<unk>  is approved for the treatment of non-small cell lung cancer in patients with an EGFR mutation who have advanced or metastatic disease.
Icotinib
Tepotinib
Crizotinib
Nilotinib
Afatinib
Imatinib
Neratinib
Acalabrutinib